Patents by Inventor Arvia E. Morris
Arvia E. Morris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11827692Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.Type: GrantFiled: March 8, 2023Date of Patent: November 28, 2023Assignee: AMGEN INC.Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
-
Publication number: 20230227535Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.Type: ApplicationFiled: March 8, 2023Publication date: July 20, 2023Applicant: AMGEN INC.Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
-
Patent number: 11685772Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.Type: GrantFiled: December 14, 2022Date of Patent: June 27, 2023Assignee: AMGEN INC.Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
-
Patent number: 11673941Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.Type: GrantFiled: September 11, 2020Date of Patent: June 13, 2023Assignee: AMGEN INC.Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
-
Publication number: 20230129523Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.Type: ApplicationFiled: December 20, 2022Publication date: April 27, 2023Applicant: AMGEN INC.Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
-
Patent number: 11634476Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.Type: GrantFiled: September 11, 2020Date of Patent: April 25, 2023Assignee: AMGEN INC.Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
-
Publication number: 20230117598Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.Type: ApplicationFiled: December 14, 2022Publication date: April 20, 2023Applicant: AMGEN INC.Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
-
Publication number: 20220185869Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.Type: ApplicationFiled: March 4, 2022Publication date: June 16, 2022Applicant: Amgen Inc.Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
-
Patent number: 11292829Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures by changing the temperature of the cell culture and/or by starving the cells in their asparagine supply.Type: GrantFiled: June 29, 2012Date of Patent: April 5, 2022Assignee: AMGEN INC.Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
-
Publication number: 20210061888Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.Type: ApplicationFiled: September 11, 2020Publication date: March 4, 2021Applicant: Amgen Inc.Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
-
Publication number: 20200407427Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.Type: ApplicationFiled: September 11, 2020Publication date: December 31, 2020Applicant: Amgen Inc.Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
-
Publication number: 20190023798Abstract: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.Type: ApplicationFiled: October 4, 2018Publication date: January 24, 2019Applicant: IMMUNEX CORPORATIONInventors: Richard J. Armitage, Jose Carlos Escobar, Arvia E. Morris, John D. Pluenneke
-
Publication number: 20180171016Abstract: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.Type: ApplicationFiled: February 9, 2018Publication date: June 21, 2018Applicant: IMMUNEX CORPORATIONInventors: Richard J. ARMITAGE, Jose Carlos ESCOBAR, Arvia E. MORRIS, John D. PLUENNEKE
-
Publication number: 20170137526Abstract: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.Type: ApplicationFiled: January 24, 2017Publication date: May 18, 2017Applicant: IMMUNEX CORPORATIONInventors: Richard J. ARMITAGE, Jose Carlos ESCOBAR, Arvia E. MORRIS, John D. PLUENNEKE
-
Patent number: 9587026Abstract: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.Type: GrantFiled: February 7, 2014Date of Patent: March 7, 2017Assignee: Immunex CorporationInventors: Richard J. Armitage, Jose Carlos Escobar, Arvia E. Morris
-
Patent number: 9388447Abstract: The present invention relates to methods for mammalian cell culture. The methods make use of independent tyrosine and cystine feed streams.Type: GrantFiled: August 7, 2015Date of Patent: July 12, 2016Assignee: AMGEN, INC.Inventors: Matthew I. Jerums, Amanda Kano, Henry Lin, Shun Luo, Jian Wu, Rebecca E. McCoy, Arvia E. Morris
-
Publication number: 20160040207Abstract: The present invention relates to methods for mammalian cell culture. The methods make use of independent tyrosine and cystine feed streams.Type: ApplicationFiled: August 7, 2015Publication date: February 11, 2016Applicant: AMGEN INC.Inventors: Matthew I. JERUMS, Amanda KANO, Henry LIN, Shun LUO, Jian WU, Rebecca E. McCOY, Arvia E. MORRIS
-
Patent number: 9133493Abstract: The present invention relates to methods for mammalian cell culture. The methods make use of independent tyrosine and cystine feed streams.Type: GrantFiled: April 20, 2012Date of Patent: September 15, 2015Assignee: AMGEN INC.Inventors: Matthew I. Jerums, Amanda Kano, Henry Lin, Shun Luo, Jian Wu, Rebecca E. McCoy, Arvia E. Morris
-
Patent number: 9012178Abstract: The present invention relates to the culture of animal cells in serum-free culture medium. The present invention provides particular dipeptides that can improve recombinant protein production and cell viability in such cultures, especially in the absence of peptones.Type: GrantFiled: August 5, 2011Date of Patent: April 21, 2015Assignee: Amgen Inc.Inventors: Sohye Kang, Rohini Deshpande, Rebecca E. McCoy, Leslie P. Miranda, Arvia E. Morris
-
Publication number: 20140255993Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures by changing the temperature of the cell culture and/or by starving the cells in their asparagine supply.Type: ApplicationFiled: June 29, 2012Publication date: September 11, 2014Applicant: AMGEN INC.Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris